French health tech company Keen Eye has launched a new artificial intelligence (AI) web-based platform to support organisations conducting clinical trials.
The computational pathology platform is Good Clinical Laboratory Practices (GCLP) compliant and will help in expediting clinical trials with deep learning-based image analysis. It will allow every actor in pathology to run digital image analysis efficiently.
The platform will address the safety of clinical trial subjects and ensure the integrity of study data. An audit trail also captures every action performed on the platform.
Keen Eye founder and CEO Sylvain Berlemont said: “It provides a quantum leap in performance while contributing to regulatory compliance, hence paving the way for better standards in clinical image analysis.
“We are proud to have developed the solution every pharma and CRO has been waiting for.”
Institut Gustave Roussy, France, former head of pathology Dr Jacques Bosq said: “As pathologists, we always put patients’ interests first. Keen Eye’s expertise in digital tissue analysis has proven to be a really effective solution.
“With this innovative GCLP-compliant platform, pathologists will be able to perform biomarker detection and quantification in clinical study protocols in a reliable, standardised and efficient manner.”
The company will demonstrate the platform’s capabilities during Oxford Global’s ‘Biomarkers UK’ event in November 2021.
Established in 2015, Keen Eye works to advance the use of AI for the benefit of biologists, pathologists and patients. The company also aims to support the development of new therapies with improved analytics.